Abstract:Objective: We investigated the effect of intramuscular injections of long-acting bromocriptine in patients with macroadenomas. Study design and patients: Thirty patients with PRL-secreting pituitary macroadenomas were treated with repeated 4-weekly intramuscular injections of 50 or 100 mg of a long-acting, repeatable bromocriptine formulation for six to 37 injections, amounting to a total of 473 injections. Twenty patients received parenteral bromocriptine as primary therapy, ten had persisting hyperprolactinemia after previous therapies including pituitary surgery (n = 7), oral bromocriptine (7), and pituitary irradiation (2). Measurements: A PRL day profile was obtained and the patients' clinical status and history were documented, at intervals. Detailed clinical, laboratory, and radiological (pituitary nuclear magnetic resonance or computed tomography scan) evaluations were performed at baseline, after 1 injection and every 6th injection thereafter. Results: In all patients PRL was suppressed from a mean +/- SEM pretreatment level of 32,620 +/- 8680 to 4480 +/- 1140 mU/I on the third day after the first injection. In 12 patients PRL levels normalized (< 400 mU/I) with the first to fourth injection, in three additional patients PRL levels normalized after 8-15 months. In 19 patients PRL was suppressed to less than 1000 mU/l. In three patients PRL did not decrease to less than 50% of pretreatment; in two of them on oral bromocriptine prior to this study there had been a comparable low efficacy. Of 28 patients with macroadenomas (median height 22 mm) tumour shrinkage was evident in 15 by nuclear magnetic resonance or computed tomography scan 28 days after the first injection, and in three additional patients after 6 months. There was further regression in seven cases after 12, 18 or 24 injections. Adenoma size (mean +/- SEM) decreased to 66 +/- 7% of the pretreatment value. The 40 adverse events noted in 20 of 30 patients during 24 hours after the first injection were similar to known side-effects of oral bromocriptine, nausea and postural hypotension being the most frequent. With repeated injections, on average 0.6 adverse events were noted per injection (mostly mild asthenia). There were no local adverse reactions at the injection site. Conclusion: We conclude that long-acting repeatable bromocriptine in patients with macroprolactinomas offers a safe and efficacious primary treatment that ensures compliance and gives long-term control. Adverse reactions are comparable to oral bromocriptine but subside with repeated injections.

Long-term treatment of acromegaly with bromocryptine: postprandial HGH levels and response to TRH and glucose administration

Response of acromegaly to long term bromocriptine therapy: a biochemical and clinical assessment

The influence of bromocriptine on serum levels of growth hormone and other pituitary hormones and its metabolic effects in active acromegaly

Bromocriptine, a dopamine agonist, increases growth hormone secretion in a patient with acromegaly

Control of prolactin-secreting macroadenomas with parenteral, long-acting bromocriptine in 30 patients treated for up to 3 years

Response of Patients with Acromegaly to Long-acting Octreotide with regard to Regression of Pituitary Adenoma, Growth Hormone and Insulin-like Growth Factor-1

Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution

Long-term bromocriptine therapy may restore the inhibitory control of prolactin release in some patients with pathological hyperprolactinemia

Complete Shrinking of Mixed Growth Hormone and Prolactin-Secreting Pituitary Adenoma with Bromocriptine Therapy Alone

Successful long-term management of a gonadotroph adenoma with bromocriptine

Bromocriptine Treatment of Invasive Giant Prolactinomas Involving the Cavernous Sinus: Results of a Long-Term Follow Up.

Preliminary studies of plasma growth hormone releasing activity during medical therapy of acromegaly

Current therapy and drug pipeline for the treatment of patients with acromegaly

Carbohydrate Tolerance and Serum Lipids in Acromegaly Before and During Treatment with High Dose Octreotide

Octreotide in the treatment of acromegaly – the possibilities of high-dose therapy

Impact of Long-Acting Somatostatin Analogues on Glucose Metabolism in Acromegaly: A Hospital-Based Study

Advances in drug treatment of acromegaly

Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly

Effect of Cabergoline on weight and glucose metabolism in patients with acromegaly

Medical treatment of acromegaly - When the tumor size matters: A narrative review

Treatment of acromegaly with oral octreotide